- Home
- OMDA vs SNDX Comparison
OMDA vs SNDX Comparison
Compare OMDA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMDA
- SNDX
- Stock Information
- Founded
- OMDA 2011
- SNDX 2005
- Country
- OMDA United States
- SNDX United States
- Employees
- OMDA N/A
- SNDX N/A
- Industry
- OMDA Medical/Nursing Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- OMDA Health Care
- SNDX Health Care
- Exchange
- OMDA Nasdaq
- SNDX Nasdaq
- Market Cap
- OMDA 1.2B
- SNDX 1.1B
- IPO Year
- OMDA 2025
- SNDX 2016
- Fundamental
- Price
- OMDA $21.32
- SNDX $16.24
- Analyst Decision
- OMDA Strong Buy
- SNDX Strong Buy
- Analyst Count
- OMDA 6
- SNDX 10
- Target Price
- OMDA $25.00
- SNDX $37.50
- AVG Volume (30 Days)
- OMDA 430.6K
- SNDX 2.9M
- Earning Date
- OMDA 08-07-2025
- SNDX 08-04-2025
- Dividend Yield
- OMDA N/A
- SNDX N/A
- EPS Growth
- OMDA N/A
- SNDX N/A
- EPS
- OMDA N/A
- SNDX N/A
- Revenue
- OMDA $209,827,000.00
- SNDX $77,933,000.00
- Revenue This Year
- OMDA $33.26
- SNDX $434.67
- Revenue Next Year
- OMDA $20.16
- SNDX $108.62
- P/E Ratio
- OMDA N/A
- SNDX N/A
- Revenue Growth
- OMDA 135.27
- SNDX 2126.66
- 52 Week Low
- OMDA $14.14
- SNDX $8.58
- 52 Week High
- OMDA $28.40
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- OMDA N/A
- SNDX 79.83
- Support Level
- OMDA N/A
- SNDX $15.36
- Resistance Level
- OMDA N/A
- SNDX $16.33
- Average True Range (ATR)
- OMDA 0.00
- SNDX 0.78
- MACD
- OMDA 0.00
- SNDX 0.31
- Stochastic Oscillator
- OMDA 0.00
- SNDX 96.87
About OMDA Omada Health Inc. Common Stock
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.